MapLight Therapeutics, Inc. Increase Decrease In Operating Lease Liability
MapLight Therapeutics, Inc. (MPLT) reported Increase Decrease In Operating Lease Liability of -$441.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-13
- MapLight Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$230.00K.
- MapLight Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$211.00K.
- MapLight Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$204.00K.
- MapLight Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$199.00K.
- MapLight Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$777.00K.
- MapLight Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$653.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$230.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$441.00K 10-Q · filed 2026-08-13 | -$645.00K derived: sum of 3 quarters · filed 2026-08-13 | -$844.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$211.00K 10-Q · filed 2026-05-14 | -$415.00K derived: sum of 2 quarters · filed 2026-05-14 | -$614.00K derived: sum of 3 quarters · filed 2026-05-14 | -$804.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$204.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$403.00K derived: sum of 2 quarters · filed 2026-03-26 | -$593.00K derived: sum of 3 quarters · filed 2026-08-13 | -$777.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | -$199.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-12-04 | -$389.00K derived: sum of 2 quarters · filed 2026-08-13 | -$573.00K 10-Q · filed 2025-12-04 | -$749.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$190.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$374.00K 10-Q · filed 2026-08-13 | -$550.00K derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-03-31 | -$184.00K 10-Q · filed 2026-05-14 | -$360.00K derived: sum of 2 quarters · filed 2026-05-14 | ||
| 2024-12-31 | -$176.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$653.00K 10-K · filed 2026-03-26 | ||
| 2024-09-30 | -$477.00K 10-Q · filed 2025-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |